Cell Counting Market Research Report Information By Product (Consumables, Instruments) By Application (Research Application, Clinical & Diagnostic Applications, Others) By End-User (Pharmaceutical & Biotechnology Companies, Hospitals, Research Institutes, Others) Forecast till 2032.

Cell Counting Market Overview

The Cell Counting Market is expected to cross USD 16.91 Billion by 2032 at a CAGR of 7.8% during the forecast period 2023-2032. Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market. 

Market Influencer

Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively. 

Cell counting is one technique for counting cells in the life sciences, such as medical diagnosis and therapy. To preserve and strengthen their positions in the market, the companies that operate in it adopt organic and inorganic growth tactics. The market is expanding thanks to the rising financing for stem cell-based research. The increased need for biologics for treating chronic diseases is one factor driving the market's rise. Managing cell concentration in biologics with spectrophotometers and flow cytometers throughout the development of these products improves the market's growth possibilities. The COVID-19 made a substantial impact on market growth. Based on an individual's genetic profile, personalized medicine seeks to provide personalized treatments.

Furthermore, sophisticated cell-counting devices are becoming increasingly popular among key industry competitors due to their wide range of applications and workflow simplicity. Devices that count cells are essential for assessing patient samples and selecting the best treatment plans. The growing emphasis on customized medicine drives the worldwide need for cell-counting devices. The prevalence of the target diseases, such as diphtheria, HIV, measles, chronic conditions like cancer, additional blood disorders, automated hematology analyzers, and high-throughput flow cytometry are both boosting the market's growth. The market has expanded due to technological advancements in cell counting consumables and equipment that have improved product introductions and adoption.

As a result, it is projected that factors including the increasing prevalence of chronic diseases, advancing technology advancements, and recent product launches within the cell counting industry will fuel the industry's growth. However, the high cost of complicated cell counting machinery and hematological analyzer product recalls may restrain market expansion. The expanding studies and development activities in the biological sciences, biotechnology, and pharmaceuticals drive the demand for cell counting equipment. Various research applications, such as the study of stem cells, drug discovery, and regenerative medicine, depend on these devices, which is driving market expansion. As lymphopenia and eosinopenia were possible COVID-19 indications, the adoption of cell counting instruments significantly increased during the pandemic. More people seek medical care for oral disorders like atrophic glossitis as knowledge of oral health and its connection to general health grows. The demand for treatment alternatives is fueled by the discovery and diagnosis of cases of atrophic glossitis, made possible by advancements in diagnostic methods and the availability of healthcare services.

Market Drivers

• The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.

• The growth of the market is driven by the increasing number of product launches in the global cell counting market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.

• Increased R&D expenditure in the healthcare industry will support the growth of the cell counting market.

• Increasing number of stem cell organizations globally support the growth of the market.

• Rising incidence & prevalence of cancer will support the growth of the market.

Market Restraints

• The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results. 

Cell Counting Market Segment Insights

Cell Counting Product Insights

• 
  Consumables:The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.

• 
  Instruments:Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.

Cell Counting Application Insights

• 
  Research Application:Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.

• 
  Clinical & Diagnostic Applications:Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.

• 
  Others:Others include industrial and other commercial applications.

Cell Counting End-User Insights

• 
  Pharmaceutical & Biotechnology Companies:The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.

• 
  Hospitals:Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.

• 
  Research Institutes:These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.

• 
  Others:These include academic institutes, among others.

Cell Counting Region Insights

• 
  Americas:The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.

• 
  Europe:The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.

• 
  Asia-Pacific:Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.

• 
  Middle East & Africa:It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.

• The debut of CytoSMART Technologies' fluorescent cell counter has been announced. A dual fluorescence cell counter with an extended field of vision and unparalleled performance is called the CytoSMART Exact FL. Although the system has a relatively small footprint, its capabilities are on par with those of most other automated cell counters, if not all of them. Thanks to various technological advances, the CytoSMART Exact FL establishes new benchmarks for performance, accuracy, and speed. Along with a more sophisticated 6.4-megapixel CMOS camera, the upgraded specifications now feature superfast autofocus, high-magnification and high-contrast lenses, a larger measurement volume, and extremely reliable picture recognition by artificial intelligence (AI) algorithms.

Key Players

• Thermo Fisher Scientific (US)


• Merck KGaA (Germany)


• Danaher Corporation (US)


• Bio-Rad Laboratories, Inc. (US)


• Logos Biosystems, Inc. (South Korea)


• Olympus Corporation (Japan)


• Agilent Technologies, Inc. (US)


• PerkinElmer, Inc. (US)


• Sysmex Corporation (Japan)


• Abbott Laboratories (US)